Lilly(US:LLY) GLP1减重宝典·2025-12-16 08:34Core Insights - The article discusses the positive results of Eli Lilly's TRIUMPH-4 clinical trial, which evaluated the efficacy and safety of retatrutide in overweight or obese adults with knee osteoarthritis as an adjunct to diet and exercise [4][5]. Group 1: Clinical Trial Results - TRIUMPH-4 is a global study with 84% of participants having a baseline BMI ≥35 kg/m², showing significant weight loss and improvement in pain and physical function at 68 weeks [5][6]. - The average weight loss was 28.7% (approximately 71.2 pounds), and the knee pain score (WOMAC) decreased by up to 4.5 points, a reduction of 75.8% [6]. - Key secondary endpoints showed high rates of extreme weight loss: 47.7% for the 9 mg group and 58.6% for the 12 mg group achieving ≥25% weight loss, with nearly 40% in the 12 mg group achieving ≥30% weight loss [7]. Group 2: Cardiometabolic Benefits - Retatrutide also significantly improved various cardiovascular risk indicators, including non-HDL cholesterol, triglycerides, and high-sensitivity C-reactive protein (hsCRP), with an average systolic blood pressure reduction of 14 mmHg in the 12 mg group [8]. Group 3: Safety Profile - The safety profile of retatrutide is consistent with other GLP-1 receptor agonists, with common adverse events including nausea, diarrhea, constipation, vomiting, and decreased appetite, mostly mild to moderate [9]. - The overall discontinuation rate due to adverse events was similar between treatment and placebo groups, with a lower rate in the high-risk population (BMI ≥35) [9]. Group 4: Future Outlook - The TRIUMPH program has enrolled over 5,800 participants, with seven additional Phase III study results expected by 2026, including lower maintenance doses (4 mg) [11]. - Eli Lilly anticipates that retatrutide could become an important treatment option for patients requiring significant weight loss and suffering from multiple obesity-related complications [11].